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Background: Bladder cancer is a significant cause of morbidity and mortality with a high recurrence rate. Early
detection of bladder cancer is essential in order to remove the tumor, to preserve the organ and to avoid
metastasis. The aim of this study was to analyze the differential expression of mitochondrial non-coding RNAs
(sense and antisense) in cells isolated from voided urine of patients with bladder cancer as a noninvasive diagnostic
assay.
Methods: The differential expression of the sense (SncmtRNA) and the antisense (ASncmtRNAs) transcripts in cells
isolated from voided urine was determined by fluorescent in situ hybridization. The test uses a multiprobe mixture
labeled with different fluorophores and takes about 1 hour to complete. We examined the expression of these
transcripts in cells isolated from urine of 24 patients with bladder cancer and from 15 healthy donors.
Results: This study indicates that the SncmtRNA and the ASncmtRNAs are stable in cells present in urine. The test
reveals that the expression pattern of the mitochondrial transcripts can discriminate between normal and tumor
cells. The analysis of 24 urine samples from patients with bladder cancer revealed expression of the SncmtRNA and
down-regulation of the ASncmtRNAs. Exfoliated cells recovered from the urine of healthy donors do not express
these mitochondrial transcripts. This is the first report showing that the differential expression of these
mitochondrial transcripts can detect tumor cells in the urine of patients with low and high grade bladder cancer.
Conclusion: This pilot study indicates that fluorescent in situ hybridization of cells from urine of patients with
different grades of bladder cancer confirmed the tumor origin of these cells. Samples from the 24 patients with
bladder cancer contain cells that express the SncmtRNA and down-regulate the ASncmtRNAs. In contrast, the
hybridization of the few exfoliated cells recovered from healthy donors revealed no expression of these
mitochondrial transcripts. This assay can be explored as a non-invasive diagnostic tool for bladder cancer.Background
Bladder cancer (BC) is an important cause of morbidity
and mortality, with an estimated 386.000 new cases and
150.000 deaths occurring worldwide in 2008 [1]. Bladder
tumors are classified into four categories: papilloma,* Correspondence: jvillegas@bioschile.cl
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reproduction in any medium, provided the orlow-grade carcinoma, high-grade carcinoma and carcin-
oma in situ [2]. About 90% of bladder cancers are
urothelial carcinomas and transitional cell carcinomas
(TCC) and the rest include squamous cell carcinomas
and adenocarcinomas. As many other types of cancer,
early detection of BC will allow effective treatments of
patients, improving long-term survival.
The “gold standard” in the detection of BC is cystos-
copy. This examination, however, is unpleasant, time
consuming, expensive and may result in infections and
urethral damage [3]. On the other hand, urine cytologyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Schematic representation of S-FISH of cells from
cultures or present in biological fluids. Cells are collected by
centrifugation at 200 x g for 10 min and the pellet suspended in
100 μl 0.2 N HCl. After washing with PBS, the cells are hybridized in
100 μl hybridization solution containing fluorescent-labeled probes
for the SncmtRNA and the ASncmtRNAs. After a stringency washing,
the cells are analyzed by fluorescence microscopy.
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grade disease [4,5]. To improve the detection of BC cells
in voided urine, several tumor markers and tests have
been developed [6,7]. One of these tests is based on
fluorescent in situ hybridization (FISH) to detect
chromosomal alterations characteristic of BC [8].
Human cells express a family of mitochondrial long
non-coding RNAs (ncRNA) containing stem-loop struc-
tures. One of these transcripts, the sense mitochondrial
ncRNA or SncmtRNA, is expressed in normal proliferat-
ing cells and tumor cells but not in non-dividing cells
[9,10]. Experimental evidences suggest that this tran-
script plays a regulatory role of the cell cycle [11]. In
addition, normal human proliferating cells in culture or
in normal human tissues express two antisense tran-
scripts, AsncmtRNA-1 and AsncmtRNA-2 [10]. Interest-
ingly, the SncmtRNA and the AsncmtRNAs exit the
mitochondria and localize to the cytoplasm and the nu-
cleus in association with chromatin and nucleoli, sug-
gesting that the function of these transcripts take place
outside the organelle [12].
The function of the ASncmtRNAs is less clear. How-
ever, an interesting observation is that the ASncmtRNAs
are down-regulated in tumor cell lines as well as in
tumor cells present in different types of human cancer
and patients [10]. In situ hybridization of twelve BC bi-
opsies from different patients shows expression of the
SncmtRNA and down-regulation of the ASncmtRNAs
[10]. Since down-regulation of the ASncmtRNAs seems
to be independent of the tissue of origin of tumor cells,
the differential expression of these transcripts can be ap-
plied as a cancer diagnostic method for cells in suspen-
sion. Here, we present a one-tube fluorescence in situ
hybridization protocol applied to cells in suspension
(S-FISH), that takes about 60 min to perform and using
simultaneously labeled probes for both SncmtRNA and
AsncmtRNAs. This method was applied to cells isolated
from urine of patients with bladder cancer (BC). In
twenty four patients with low and high grade of BC,
S-FISH revealed cells expressing the SncmtRNAs and
not the ASncmtRNAs, hence corresponding to cancerTable 1 Distribution of tumor stage and grade among all
patients included in this study
Grade and stage
distribution None Grade 1 Grade 2 Grade 3 Total
No tumor 15 15
Ta 11 2 4 17
T1 1 1 1 3
T2-4 3 3
CIS 1 1
Total 15 12 3 9 39cells phenotype. The expression of these transcripts was
negative in the few cells isolated from the urine of
healthy donors. The differential expression of the
SncmtRNA and the ASncmtRNAs in cells isolated from
voided urine can be explored as a new non-invasive
diagnostic test for BC.Methods
Tumor cell culture
T24 and RT4 cells (human bladder carcinoma) and
DU-145 cells (prostate carcinoma) were cultured accord-
ing to ATCC recommendations. Cultures were maintained
in a humidified incubator at 37°C and 5% CO2. Peripheral
blood mononuclear cells (PBMC) from healthy donors
were isolated and stimulated with phytohaemagglutinin
(PHA) for 48 h as described before [9,10,13]. Primary
renal mixed epithelial cells were obtained from ATCC and
cultured according to ATCC guidelines.














Figure 2 Hybridization kinetics on T-24 cells. After trypsinization, 105 cells were collected by centrifugation at 200 x g for 10 min and the
pellet was subjected to S-FISH as indicated in Figure 1. Cells were hybridized simultaneously with probes complementary to the SncmtRNA and
ASncmtRNAs for 15, 30, 60 and 120 min. Only the green signal corresponding to the expression of the SncmtRNA was observed, while expression
of the ASncmtRNAs was down-regulated (red fluorescence). Cell distribution was revealed with DAPI staining (DAPI). The positive control
corresponding to Texas red-labeled 18S rRNA-probe was run in parallel (60x).
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All the hybridization steps were performed in MaxiRe-
covery™ tubes of 0.5 ml (Axygen Scientific, US). After
trypsinization (Invitrogen, Carlsbad, US), about 105 cells
were recovered by centrifugation at 200 × g for 10 min
at room temperature (RT). The cell pellet was resus-
pended in 100 μl HCl 0,2 N and incubated for 5 min at
RT. Afterwards, the cell suspension was diluted with
400 μl PBS (50 mM sodium phosphate, 150 mM NaCl
and 2 mM EDTA, pH 9.0) and centrifuged again. The
sediment was resuspended in 100 μl hybridization buffer
(50% formamide, 150 μg/ml herring sperm DNA, 4X SSC,
2 mM EDTA) containing 0,5 μM 50-Alexa fluor 488-
labeled probe P1 (50 GTTCTTGGGTGGGTGTGGG 30),
complementary to the SncmtRNA and 0,05 μM each of
two 50 Texas Red-labeled probes P2 (50 GATAACAGCG
CAATCCTATT 30) and P3 (50 ACCGTGCAAAGGTAG
CATAATCA 30), complementary to the ASncmtRNAs. In
addition, two negative controls corresponding to mis-
match probes P5 for the SncmtRNA (MM: 50 TTTATTT
GATGAGTGTGAG 30), labeled with Alexa fluor 488 and
probe P6 for the ASncmtRNAs (MM: 50 GTAAAGATAG
TATAATAATTTATTAATTAAATATA 30), labeled withTexas Red at the 50 end. The labeled probes were obtained
from Invitrogen (Carlsbad, CA, USA).
Hybridization was carried out for 15 min to 2 h at
37°C. The final wash was performed by addition of four
volumes of stringency buffer (2X SCC + 2 mM EDTA) to
the hybridization mix, incubated for 5 min at 37°C and
finally centrifuged at 200 × g for 10 min. The super-
natant was discarded and a small volume of approxi-
mately 20 μl of the residual supernatant was left in the
tube to resuspend the cells. The cells were finally stained
in a solution of 1 μg/ml DAPI, deposited onto a positively
charged slide (Thermo Scientific, US) and mounted in
fluorescent medium (DAKO). Samples were analyzed by
fluorescence microscopy on an Olympus BX-51 micro-
scope under x600 magnification, with 300-600 ms expos-
ition and results were documented with Q-capture Pro
software. The positive hybridization control corresponded
to a 50-Texas Red-labeled probe complementary to 18S
rRNA (P4: 50 AGTGGACTCATTCCAATTACA 30).
Voided urine
About 30-50 ml voided urine from male and female
healthy donors was carried out in agreement with the
SncmtRNA ASncmtRNA 18S rRNADAPIA
MM MM
MM MM
SncmtRNA ASncmtRNA DAPI 18S rRNA
B
Figure 3 Stability of the mitochondrial ncRNAs in urine. A, 5 × 104 T-24 cells were loaded in urine obtained from healthy donors and stored
at 4°C for 24 h. Cells were then recovered by centrifugation as described and subjected to S-FISH. Only the SncmtRNA (green fluorescence) was
detectable, while probes for ASncmtRNAs (red fluorescence) showed absence of signal, as did the corresponding mismatch probes (MM, green or
red). The cells were also counterstained with DAPI. A parallel sample was hybridized with a probe specific for the 18S rRNA (18S rRNA). B, DU-145
cells (prostate carcinoma) were subjected to the same S-FISH protocol. Notice that the cells only express the SncmtRNA. No fluorescent signal
was obtained with the probes targeted to the ASncmtRNA or with MM probes.
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the Fundacion Ciencia para la Vida. The urine from
healthy donors (50 ml) was loaded with 5×104 to 1×105
T24 or DU-145 cells or PHA-stimulated lymphocytes
and incubated at 4°C for 24 h. The cells were sedimen-
ted by centrifugation at 700 × g for 10 min. The super-
natant was discarded, leaving only 5 ml, which were
transferred to a Kova tube (Hycor Biomedical Inc., US)
and centrifuged again at 200 × g for 10 min at RT. Most
of the supernatant was discarded and the remnant
(~1ml) was transferred to a 0,5 ml Maxy-Recovery tube
(Axygen Scientific, US), centrifuged at 200 × g and sub-
jected to S-FISH as described above.
Twenty four patients diagnosed with BC were
recruited at the Urology Unit of the Hospital Barros
Luco Trudeau and Clinica Indisa (Santiago, Chile). The
urine samples were obtained with informed consent
under the Ethical Regulations of the Hospital Barros
Luco Trudeau and Clinica Indisa and with the approval
of the Ethic Committee of Fundacion Ciencia para laVida. The tumor biopsies were graded as reported [14]
and the data are summarized in Table 1. The first-
morning voided urine (50 ml) was collected and stored
at 4°C in a cooler and transported to the laboratory. The
urine was centrifuged at 700 × g for 10 min within 4 h
after collection and S-FISH was performed as described
above. Parallel samples were stained with hematoxylin.
Results
Optimization of the S-FISH protocol
A schematic representation of the S-FISH is shown in
Figure 1. Briefly, cells were collected by centrifugation
from cell culture or from biological fluids such as urine
and blood, followed by permeabilization with 0.2 N HCl.
After neutralization, the cells were recovered, hybridized
with a set of probes labeled with fluorophores, washed
and analyzed by fluorescence microscopy (see Methods).
To determine the minimum hybridization time needed
for the detection of the mitochondrial ncRNAs, T-24
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hybridization the fluorescent signal of the SncmtRNA
was as strong and specific as longer hybridization
times (Figure 2, SncmtRNA). The red signal correspond-
ing to the ASncmtRNA was negative at any of the
hybridization times tested confirming the tumor pattern
of expression of T-24 cells (Figure 2, ASncmtRNAs). The
18S rRNA used as positive control was expressed in all
cells and the corresponding red signal was also inde-
pendent of hybridization times ranging from 15 to
120 min (Figure 2, 18S rRNA, red). The same results
were obtained with the bladder carcinoma cell line RT4
(unpublished data).18S rRNA DAPIMM
Figure 4 Normal proliferating cells express the SncmtRNA and
the ASncmtRNAs. A, PHA-stimulated human lymphocytes were
hybridized simultaneously with probes complementary to the
SncmtRNA and ASncmtRNA. After 15 min of hybridization, strong
signals were obtained with both probes in the same cells. No signal
was observed with the corresponding mismatch probes (MM, green
or red fluorescence). (60x). B, Kidney epithelial cells express both
mitochondrial transcripts. The S-FISH revealed that the same cells (as
revealed by DAPI staining) expressing the SncmtRNA also express
the ASncmtRNAs. The mismatch control (MM) was negative and 18S
probe was used as a positive control (60x).Stability of the mitochondrial ncRNAs in urine
An interesting model to test S-FISH was cancer cells
obtained from voided urine of patients with BC. Since
the stability of cells and their RNAs in urine is uncertain,
we asked whether the urine would affect the stability of
the SncmtRNA and the ASncmtRNAs from tumor cells
and normal proliferating cells. Fresh urine of healthy
donors was loaded with 5×104 T-24 cells/ml and main-
tained at 4°C for 24 h. Cells were then recovered by cen-
trifugation and subjected to S-FISH as described.
Analysis of several fields indicated that all cells were
positive for the SncmtRNA and the intensity of the
fluorescent signal was comparable to that of fresh T-24
cells (compare Figures 2 and 3, SncmtRNA). The red
hybridization signal corresponding to the ASncmtRNAs
(Figure 3A, ASncmtRNAs) was negative and comparable
to the negative green fluorescence of the mismatch
(MM) probes for the sense transcript (Figure 3A, panels
MM green) or the red fluorescence of the MM probe for
the antisense transcripts (Figure 3A, panels MM red).
The hybridization signal of 18S rRNA was similar to that
of fresh T-24 cells (Figure 3A, 18S rRNA). The same
results were obtained with DU-145 cells (prostate car-
cinoma cell line) (Figure 3B).
In addition, we determined the stability of the
SncmtRNA and the ASncmtRNAs in normal proliferat-
ing cells maintained in urine for 24 h at 4°C. Isolated
PBMC were activated with PHA and incubated in urine
for 24 h previous to S-FISH. PHA-stimulated PBMCs
showed a positive signal for both the SncmtRNA and
the ASncmtRNAs (Figure 4A) confirming the expression
pattern of normal proliferating cells [10]. On the other
hand, the hybridization signals were negative with the
MM probe to either the SncmtRNA (green fluorescence)
and the ASncmtRNAs (red fluorescence) (Figure 3A,
MM). Similarly, the same normal renal epithelial cells
(DAPI staining) expressing the SncmtRNA were also
expressing the ASncmtRNAs (Figure 4B). The green
mismatch control was negative (Figure 4B).Detection of tumor cells in voided urine of patients
with BC
Then we asked whether S-FISH can be applied to tumor
cells present in voided urine obtained from 24 patients
with BC diagnosed by cystoscopy and confirmed by bi-
opsy. Table 1 show the grade and stage distribution of
the samples. The cells were recovered from urine 4 h
after collection and subjected to S-FISH as described be-
fore. Then, 25 fields of each sample at 40x magnification
were analyzed and recorded. In all 24 urine samples, the
S-FISH detects cells expressing the SncmtRNA and
down-regulate the ASncmtRNAs. As described before,
this expression pattern corresponds to a cancer cells.
Figure 5 illustrates S-FISH results obtained with urine
cells recovered from four patients with BC. Samples A,
B and C correspond to urine cells recovered from
patients with grade 3 BC (Figure 5). Samples D corre-
sponds to cells obtained from patients with grade 2
(Figure 5). It is important to mention that the cellularity






Figure 5 Representative S-FISH of tumor cells obtained from urine from patients with BC. Cells were collected by centrifugation from
three grade 3 BC patients (A to C) and one grade 2 BC patient (D). The cells were hybridized simultaneously with probes complementary to the
SncmtRNA and the AsncmtRNAs. After hybridization, cells were stained with DAPI. Only the SncmtRNA was detected in cells from the four
samples. A parallel sample was stained with H&E (60×).
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that only express the SncmtRNA. In six urine samples
obtained from the 15 healthy donors (Table 1) few cells
were recovered. However, the hybridization signals indi-
cate that the SncmtRNA and the ASncmtRNAs were
down-regulated. The typical debris present in some urine
samples did not interfere with the hybridization signal.
Discussion
FISH provides an important tool for conventional cyto-
genetics and evaluation of chromosomal abnormalities
associated with several malignancies [15]. Some exam-
ples of chromosomal abnormalities are found in several
diseases, such as BC [16-20], multiple myeloma [21-23],
breast cancer [24], hematological malignancies [25-28]
and lung cancer [29,30] among others. Different types of
tumor require specific sets of probes corresponding to
particular chromosomal deletions/translocations charac-
teristic of each cancer. Sokolova et al. reported the de-
velopment of a FISH assay with high sensitivity and
specificity for high grade BC using four labeled probes
specific for the pericentromeric regions of chromosomes
3, 7 and 17 and for the detection of the 9p21 deletion[8]. These results were confirmed in later studies with a
large cohort of BC patients [16-20] using several probes
combined into a single multiprobe cocktail, to detect
polysomy of chromosomes 3, 7 and 17 and homozygous
deletion of 9p21 in the urine of BC patients (Urovysion,
Abbot Molecular/Vysis, Des Plaines, IL). However, this
test has low sensitivity for low-stage and low-grade
tumors, which are the main group that recur [3].
The S-FISH assay described here is able to detect
the differential expression of the SncmtRNA and the
ASncmtRNAs in normal and cancer cells. This a sim-
ple protocol that was optimized in three steps includ-
ing a single permeabilization step with HCl, a short
hybridization step and a brief washing that basically
involves the dilution of the hybridization mix with
stringency buffer (Figure 1). The protocol contains
only three centrifugation steps in the same tube, min-
imizing the manipulation of cells and therefore maxi-
mizing RNA preservation and cell recovery. This test
is reproducible and has been applied to other normal
and tumor cell lines. Hybridization of normal prolifer-
ating cells (human umbilical vein endothelial cells, ker-
atinocytes and melanocytes) reveals the expression of
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tumor cell lines such as HeLa, 42/95 and SK-MEL-2
(melanoma), Jurkat and HL-60 (leukemia) and MDA-
MB-231 (breast carcinoma), S-FISH revealed expres-
sion of the SncmtRNA and down-regulation of the
ASncmtRNA (unpublished data).
Moreover, S-FISH was able to detect cancer cells in
urine from twenty four patients with BC and the results
were independent of the grade of BC and the urine cel-
lularity (see Figure 5). Taken together, the results suggest
that the diagnostic test has a very high positive outcome
independent of the grade and the amount of cells recov-
ered from urine of patients with BC. In the urine from
healthy donors, cells were recovered only from six out of
fifteen samples and the S-FISH revealed absence of sig-
nal to both transcripts.Conclusions
Taken together, this pilot study suggests that S-FISH
could be used for detection and regular surveillance pro-
grams of patients with BC. Interestingly, the results indi-
cate that the exfoliated bladder tumor cells from low
and high grade BC conserve the expression pattern
observed in bladder cancer biopsies: expression of the
SncmtRNA and down-regulation of the ASncmtRNAs.
In summary, S-FISH may potentially be used as a non-
invasive diagnostic test for bladder cancer. However, to
validate the test, a large cohort of patients with low-
grade and high-grade neoplasms should be included
together with other urological diseases such as glomer-
ulonephritis, infections of the upper urinary track and
other benign urinary track diseases.
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